Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 9,100 shares, a decrease of 79.8% from the October 15th total of 45,100 shares. Based on an average trading volume of 150,800 shares, the short-interest ratio is presently 0.1 days.

Astellas Pharma Trading Down 1.7 %

Shares of OTCMKTS:ALPMY opened at $10.74 on Thursday. The company has a 50 day moving average of $11.78 and a 200-day moving average of $10.95. The firm has a market cap of $19.44 billion, a P/E ratio of 18.20 and a beta of 0.36. Astellas Pharma has a twelve month low of $9.15 and a twelve month high of $13.14. The company has a current ratio of 0.90, a quick ratio of 0.72 and a debt-to-equity ratio of 0.26.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $3.11 billion during the quarter. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.33%. As a group, analysts anticipate that Astellas Pharma will post 0.62 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.